1.	Phase I/II Study of Brostallicin in Patients With Recurrent or Refractory Multiple Myeloma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CWRU-PHAR-1A02, PHARMACIA-196-ONC-0100-006, NCT00060203
2.	Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Phase: Phase II Type: Treatment Status: Completed Age: Over 15 Sponsor: Other Protocol IDs: EORTC-62011, NCT00041249
3.	Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CDR0000520404, EORTC-62061, EUDRACT-2006-001861-40, NERVIANO-BRTA-0100-015, NCT00410462
4.	Brostallicin Clinical Trial for Myxoid Liposarcoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SMI-BRS-202, NCT00633165
5.	Phase II Study of Brostallicin and Cisplatin in Patients With Triple-Negative Metastatic Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N0937, N0937, NCT01091454